Sirona Biochem Corp. (V:SBM*CA)

Business Focus: Biotechnology & Medical Research

Oct 30, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067/
VANCOUVER, Oct. 30, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that testing of the higher concentration formulation of TFC-1067, first announced in June 2019, will proceed to Human Patch Test, followed by a Human Repeat Insult Patch Test (HRIPT).
Oct 30, 2019 03:00 am ET
Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067
VANCOUVER, Oct. 30, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that testing of the higher concentration formulation of TFC-1067, first announced in June 2019, will proceed to Human Patch Test, followed by a Human Repeat Insult Patch Test (HRIPT).
Oct 23, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067/
VANCOUVER, Oct. 23, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has engaged Mr. Pinqiao Zhao, an applied chemistry engineer from Shanghai, as a consultant to assist Sirona in selecting a manufacturer in China, and to communicate the necessary technical information for production of Sirona's innovative skin lightening compound TFC-1067.
Oct 23, 2019 03:00 am ET
Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067
VANCOUVER, Oct. 23, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has engaged Mr. Pinqiao Zhao, an applied chemistry engineer from Shanghai, as a consultant to assist Sirona in selecting a manufacturer in China, and to communicate the necessary technical information for production of Sirona's innovative skin lightening compound TFC-1067.
Oct 15, 2019 07:58 am ET
Sirona Biochem: Agreement Signing Ceremony with Rodan + Fields at Cosmetic 360 Conference in Paris
VANCOUVER, Oct. 15, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it will have a signing ceremony of its TFC-1067 License and Supply agreement with Rodan + Fields, LLC ("Rodan + Fields"). Rodan + Fields, the leading skin care brand in the United States1, is preparing to incorporate novel ingredient TFC-1067 into their product lines. Backed by extensive scientific research, TFC-1067 is clinically proven to be safe and effective at reducing the visibility of dark spots, brightening and evening skin tone.
Oct 09, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China/
VANCOUVER, Oct. 9, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that it has completed a binding term sheet with Tinyi Trading Company ("Tinyi") for the distribution of its skin lightener TFC-1067 following strong commercial interest after clinical trial results. Tinyi will have distribution rights within Asia as well as exclusive rights for China.
Oct 09, 2019 03:00 am ET
Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China
VANCOUVER, Oct. 9, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that it has completed a binding term sheet with Tinyi Trading Company ("Tinyi") for the distribution of its skin lightener TFC-1067 following strong commercial interest after clinical trial results. Tinyi will have distribution rights within Asia as well as exclusive rights for China.
Sep 25, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem to Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France/
VANCOUVER, Sept. 25, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announced that its Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will represent Sirona at Cosmetic 360 in Paris, October 16-17, 2019. Since 2015, Cosmetic 360 has become an exclusive international event that allows the most influential cosmetic companies and industry decision makers to access the latest advancements in science.
Sep 25, 2019 03:00 am ET
Sirona Biochem to Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France
VANCOUVER, Sept. 25, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announced that its Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will represent Sirona at Cosmetic 360 in Paris, October 16-17, 2019. Since 2015, Cosmetic 360 has become an exclusive international event that allows the most influential cosmetic companies and industry decision makers to access the latest advancements in science.
Sep 18, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields/
VANCOUVER, Sept. 18, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is excited to announce that it has completed a definitive agreement with Rodan + Fields, LLC ("Rodan + Fields"), the leading skin care brand in the United States1, for the licensing and commercial sales of novel ingredient TFC-1067 to brighten and even skin tone. Rodan and Fields will be the first to market for a consumer product utilizing TFC-1067 in certain countries including United States.
Sep 11, 2019 09:00 am ET
Sirona Biochem Adopts Shareholder Rights Plan
VANCOUVER, Sept. 11, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that its board of directors has approved the adoption of a shareholder rights plan (the "Rights Plan"). The Rights Plan is subject to acceptance by the TSX Venture Exchange ("TSXV") and ratification by Sirona's shareholders within six months. If the shareholders do not ratify the Rights Plan at the AGM, the Rights Plan and all the rights outstanding at the time will terminate.
Jul 10, 2019 09:00 am ET
Sirona Biochem Announces Successful Close of Oversubscribed Private Placement
VANCOUVER, July 10, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) ("Sirona") is very pleased to announce today that it closed its private placement (Private Placement") as oversubscribed for gross proceeds of $1,500,000 CAD. The Private Placement consists of 3,750,000 units, (the "Units") at a price of $0.40 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.60 per share subject to an accel
Jul 09, 2019 04:15 pm ET
Sirona Biochem Announces Proposed Strategic Equity Investment
Proceeds to be used for establishing Asia-based manufacturing for TFC-1067
Jul 04, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Releases CEO Letter to Shareholders/
VANCOUVER, July 4, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to provide a corporate update from the Company's CEO, Dr. Howard Verrico, regarding its plans both near and long term in the following Q&A format. The questions, for the most part, are derived from inquiries received from investors:
Jul 04, 2019 03:01 am ET
Sirona Biochem Releases CEO Letter to Shareholders
VANCOUVER, July 4, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to provide a corporate update from the Company's CEO, Dr. Howard Verrico, regarding its plans both near and long term in the following Q&A format. The questions, for the most part, are derived from inquiries received from investors:
Jul 03, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Announces SGLT2 Inhibitor Development Progress/
VANCOUVER, July 3, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that clinical development of Sirona's SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events.
Jul 03, 2019 03:01 am ET
Sirona Biochem Announces SGLT2 Inhibitor Development Progress
VANCOUVER, July 3, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that clinical development of Sirona's SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events.
Jun 20, 2019 02:02 pm ET
Sirona Biochem Reports 2019 AGM Voting and CEO Update
VANCOUVER, June 20, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on June 20, 2019. The total number of shares represented by shareholders present in person and by proxy at the meeting was 32,141,666 million representing 15.47% of Sirona's issued and outstanding Common Shares.
Jun 19, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields/
VANCOUVER, June 19, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce that a non-binding term sheet has been signed with Rodan + Fields, LLC (Rodan + Fields) for the commercial sales of novel ingredient TFC-1067. This term sheet covers all material terms and conditions of a definitive agreement with San Francisco-based, industry leading, Rodan + Fields. The definitive agreement is expected to be signed in Q3/2019.
Jun 19, 2019 03:01 am ET
Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields
VANCOUVER, June 19, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce that a non-binding term sheet has been signed with Rodan + Fields, LLC (Rodan + Fields) for the commercial sales of novel ingredient TFC-1067. This term sheet covers all material terms and conditions of a definitive agreement with San Francisco-based, industry leading, Rodan + Fields. The definitive agreement is expected to be signed in Q3/2019.
Jun 17, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Announces TFC-1067 Skin Lightening Patent Granted in USA/
VANCOUVER, June 17, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that the patent for TFC-1067 entitled "Gem Difluorocompounds as Depigmenting or Lightening Agents" was granted in the USA, as expected, and will be published in the official database in the coming month. To date, the TFC-1067 skin lightening patent has been granted in Germany, France, United Kingdom and now the US. Further TFC-1067 patent applications are in the patent pending status in multiple other countries while they go through the normal approval process.
Jun 17, 2019 03:01 am ET
Sirona Biochem Announces TFC-1067 Skin Lightening Patent Granted in USA
VANCOUVER, June 17, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that the patent for TFC-1067 entitled "Gem Difluorocompounds as Depigmenting or Lightening Agents" was granted in the USA, as expected, and will be published in the official database in the coming month. To date, the TFC-1067 skin lightening patent has been granted in Germany, France, United Kingdom and now the US. Further TFC-1067 patent applications are in the patent pending status in multiple other countries while they go through the normal approval process.
Jun 12, 2019 08:00 am ET
Sirona Biochem Appoints Chinese Lawyer Jason Tian to its Board of Directors
VANCOUVER, June 12, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that Mr. Jason Tian will be joining its Board of Directors. Jason Tian is a Senior Partner at Landing Law offices based in Shanghai, China. Jason has been working with Sirona since 2018 representing the Company at strategic partnering meetings in China and France.
Jun 11, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Reports Approval to Test Higher Concentrations of Skin Lightening Compound TFC-1067/
VANCOUVER, June 11, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that it will assess its novel skin lightener, TFC-1067, at a concentration 3 times higher than what was used in the previous clinical trial. Higher dosing is expected to have increased efficacy, but also the potential to work more quickly than the clinically effective dose established for TFC-1067. This positive development is of substantial commercial interest to potential cosmetic partners in North America and China who share Sirona's goal to maximize efficacy without compromisin
Jun 11, 2019 03:01 am ET
Sirona Biochem Reports Approval to Test Higher Concentrations of Skin Lightening Compound TFC-1067
VANCOUVER, June 11, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that it will assess its novel skin lightener, TFC-1067, at a concentration 3 times higher than what was used in the previous clinical trial. Higher dosing is expected to have increased efficacy, but also the potential to work more quickly than the clinically effective dose established for TFC-1067. This positive development is of substantial commercial interest to potential cosmetic partners in North America and China who share Sirona's goal to maximize efficacy without compromisin
May 28, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Reports Excellent Preliminary Safety Assessment of Lead Anti-Wrinkle Compound LIP-01/
VANCOUVER, May 28, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce safety testing on its lead glycoprotein compound in the anti-wrinkle program yielded excellent results and the company will immediately move to the next steps of development. This project was generously supported by BPI France and the region Haute Normandie.
May 28, 2019 03:01 am ET
Sirona Biochem Reports Excellent Preliminary Safety Assessment of Lead Anti-Wrinkle Compound LIP-01
VANCOUVER, May 28, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce safety testing on its lead glycoprotein compound in the anti-wrinkle program yielded excellent results and the company will immediately move to the next steps of development. This project was generously supported by BPI France and the region Haute Normandie.
May 22, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067/
VANCOUVER, May 22, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce it has commissioned Contract Research Organization (CRO) Roowin (www.roowin.com) to develop the final chemical process required for large scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona's novel skin lightening agent.
May 22, 2019 03:01 am ET
Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067
VANCOUVER, May 22, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce it has commissioned Contract Research Organization (CRO) Roowin (www.roowin.com) to develop the final chemical process required for large scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona's novel skin lightening agent.
May 15, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Receives Positive Clinical Results of its Skin Lightening Compound TFC-1067 from China/
VANCOUVER, May 15, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) ("Sirona") is pleased to announce results of a clinical trial performed in the Peoples Republic of China (China) using Sirona's novel skin lightening agent TFC-1067. Sirona's TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.
May 15, 2019 03:01 am ET
Sirona Biochem Receives Positive Clinical Results of its Skin Lightening Compound TFC-1067 from China
VANCOUVER, May 15, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) ("Sirona") is pleased to announce results of a clinical trial performed in the Peoples Republic of China (China) using Sirona's novel skin lightening agent TFC-1067. Sirona's TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.
Apr 10, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem's TFC-1067 Demonstrates Superiority to Hydroquinone for the Treatment of Dyschromia/
VANCOUVER, April 10, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") is pleased to announce the results of its clinical trial performed by Dr. Zoe Draelos of Dermatology Consulting Services, conducted in North Carolina, USA. Sirona's TFC-1067 demonstrates superiority to the gold standard, hydroquinone, for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin).
Apr 10, 2019 03:01 am ET
Sirona Biochem's TFC-1067 Demonstrates Superiority to Hydroquinone for the Treatment of Dyschromia
VANCOUVER, April 10, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") is pleased to announce the results of its clinical trial performed by Dr. Zoe Draelos of Dermatology Consulting Services, conducted in North Carolina, USA. Sirona's TFC-1067 demonstrates superiority to the gold standard, hydroquinone, for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin).
Feb 27, 2019 10:40 am ET
Sirona Biochem Announces Close of Oversubscribed Private Placement
VANCOUVER, Feb. 27, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the "Company") announced today that it has closed an oversubscribed, non-brokered private placement for gross proceeds of $1,783,500. The private placement consists of 17,835,000 units, (the "Units") at a price of $0.10 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant is exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.16 per share.
Feb 26, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem to Exhibit at PCHi 2019 in Guanzhou China/
VANCOUVER, Feb. 26, 2019 /CNW/ -  Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it will exhibit at The Personal Care and Homecare Ingredients trade show (PCHi 2019) in Guanzhou China Feb 26-28th 2019. The PCHi 2019 trade show is China's #1 sourcing platform for the global personal care industry  https://www.pchi-china.com/en/. Sirona will be principally promoting its novel skin lightening agent TFC-1067 in addition to its anti-wrinkle and anti-aging compounds.
Feb 26, 2019 02:01 am ET
Sirona Biochem to Exhibit at PCHi 2019 in Guanzhou China
VANCOUVER, Feb. 26, 2019 /CNW/ -  Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it will exhibit at The Personal Care and Homecare Ingredients trade show (PCHi 2019) in Guanzhou China Feb 26-28th 2019. The PCHi 2019 trade show is China's #1 sourcing platform for the global personal care industry  https://www.pchi-china.com/en/. Sirona will be principally promoting its novel skin lightening agent TFC-1067 in addition to its anti-wrinkle and anti-aging compounds.
Feb 15, 2019 04:00 pm ET
Sirona Biochem Announces Financing
VANCOUVER, Feb. 15, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) the "Company") announced today that it has arranged a non-brokered private placement for gross proceeds of $1,000,000. The private placement consists of 10,000,000 units, (the "Units") at a price of $0.10 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.16 per share.
Feb 13, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem Advances Skin Lightener TFC-1067 Development and IP Protection in Anticipation of Licensing Discussions/
VANCOUVER, Feb. 13, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has advanced the commercial development and IP protection of its novel skin lightening agent TFC-1067.
Feb 13, 2019 02:01 am ET
Sirona Biochem Advances Skin Lightener TFC-1067 Development and IP Protection in Anticipation of Licensing Discussions
VANCOUVER, Feb. 13, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has advanced the commercial development and IP protection of its novel skin lightening agent TFC-1067.
Feb 06, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067/
VANCOUVER, Feb. 6, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona's skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
Feb 06, 2019 02:01 am ET
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
VANCOUVER, Feb. 6, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona's skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
Jan 30, 2019 08:00 am ET
Jan 30, 2019 02:01 am ET
Sirona Biochem releases CEO Letter to Shareholders
Clinical trial results expected Q1 2019
Dec 11, 2018 07:00 am ET
Sirona Biochem's SGLT2 Inhibitor in Testing for Animal Health
VANCOUVER, Dec. 11, 2018 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announced today that testing has commenced for the SGLT2 inhibitor, TFC-039, in cats.
Nov 06, 2018 07:00 am ET
Sirona Biochem Begins Proof of Efficacy Clinical Trial for TFC-1067
VANCOUVER, Nov. 6, 2018 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") reported today the successful launch of the clinical trial for skin-lightener TFC-1067 with leading dermatologist Dr. Zoe Draelos.
Oct 17, 2018 08:00 am ET
Sirona Biochem Engages Consultant for Japanese Market Penetration
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to announce that it has engaged Mr. Sven Harpering, a Tokyo-based consultant, with the help of its strategic advisory firm, PRC Partners (“PRC”) to fast-track...
Oct 16, 2018 06:00 pm ET
Sirona Biochem Announces Close of Financing and Extension of Convertible Notes
Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (the “Company”) announced that it has closed a private placement (subject to TSX.V approval) in the amount of 7,095,100 units at $0.10 per unit for total gross proceeds of $709,510. Each unit...
Oct 11, 2018 08:00 am ET
Sirona Biochem to Present at the 2018 Arctic Circle Assembly
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Arctic Circle Assembly. This conference will take place October 19th –...
Sep 28, 2018 08:00 am ET
Sirona Biochem CEO’s Report on Progress
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) provided a shareholder corporate update today from the Company’s CEO, Dr. Howard J Verrico. Dear Shareholders, As the summer comes to a close and we enter the final months...
Sep 26, 2018 08:00 am ET
Sirona Biochem Receives Positive Safety Data for Lead Skin-Lightener in Preparation for Clinical Trial in the US
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to report further progress regarding the clinical development of its lead skin-lightener, TFC-1067. In parallel with ongoing partnering discussions, Sirona has...
Aug 28, 2018 08:00 am ET
Sirona Biochem Receives $500,000 USD Milestone Payment from Wanbang Biopharmaceuticals
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) announced that it has received the $500,000 USD milestone payment from partner Wanbang Biopharmaceuticals Co., Ltd (“Wanbang”) for approval by the China Food and Drug...
Jul 12, 2018 08:00 am ET
Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial
Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that partner, Jiangsu Wanbang Biopharmaceuticals (“Wanbang”), has confirmed the Investigational New Drug (IND) submission to China’s Food and Drug Administration (CFDA) for...
May 14, 2018 10:19 pm ET
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Corp. (TSX-V:SBM) (FRANKFURT:ZSB), announces an extension to the term of 2,073,750 common share purchase warrants (the “Warrants”) originally issued on May 11, 2016. The warrants were issued as part of a private placement. The expiry...
Apr 30, 2018 08:00 am ET
Sirona Biochem to Exhibit at the Shanghai China Beauty Expo 2018
VANCOUVER, British Columbia, April 30, 2018 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that they will be exhibitors at China Beauty Expo (CBE) 2018. The trade show will be held May 22-24 in...
Feb 02, 2018 02:53 pm ET
Sirona Biochem Announces Chief Scientific Officer to Present at Adaptations in Polar Environments and Biomimicry
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Paris symposium: Adaptations in Polar Environments...
Jan 31, 2018 08:00 am ET
Sirona Biochem Announces Development of Anti-Wrinkle Treatment and Update from J.P. Morgan Healthcare Conference
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that the Company is developing an anti-wrinkle therapy. The compound, LIP-01, was discovered to have a novel mechanism of action and will enter...
Jan 29, 2018 08:00 am ET
Sirona Biochem Announces Receipt of $500,000 US Milestone Payment
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce that the $500,000 USD payment from Wanbang Biopharmaceuticals has been received. The Company now awaits the China Food and Drug...
Dec 29, 2017 08:00 am ET
Sirona Biochem Announces SGLT2 IND Submission Milestone
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that partner Jiangsu Wanbang Biopharmaceuticals has confirmed an Investigational New Drug (IND) submission to China's Food and Drug Administration...
Dec 19, 2017 04:00 pm ET
Sirona Biochem Announces Results of AGM & CEO Update
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that all resolutions tabled at its Annual General Meeting held on December 18, 2017, were passed. The resolutions included:Fixing the number of directors...
Nov 20, 2017 05:38 pm ET
Sirona Biochem Announces Grant of Stock Options
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that it has granted an aggregate of 2,350,000 bonus and incentive stock options to management, independent directors and consultants of the Company. The...
Oct 27, 2017 07:00 pm ET
Sirona Biochem Announces Resignation of Board Director
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of Mr. David Moore from the board of directors due to conflicting commitments. "We are very thankful to Mr. Moore for his contributions and...
Oct 26, 2017 01:34 pm ET
Sirona Biochem Announces Close of Oversubscribed Private Placement
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that it has closed an oversubscribed, non-brokered private placement for gross proceeds of $635,000. The private placement consists of 4,233,333...
Oct 24, 2017 09:04 pm ET
Sirona Biochem Announces Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that it has arranged a non-brokered private placement for gross proceeds of $535,000. The private placement consists of 3,566,667 units, (the...
Oct 16, 2017 08:00 am ET
Sirona Biochem to Present Kel-01 at Cosmetic 360 in Paris, France
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") announced that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will attend and present on the trade floor at Cosmetic 360 in Paris, France on...
Sep 27, 2017 08:00 am ET
Sirona Subsidiary, TFChem, Receives Final Loan Tranche from French Public Investment Bank for Anti-Aging Project
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") announced that its wholly-owned French subsidiary, TFChem, has received the final tranche of the CDN$1.2 million from Bpifrance (the French Public Investment...
Sep 21, 2017 08:00 am ET
Sirona Biochem CEO's Report on Progress
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to provide a corporate update. Dear Shareholders,I would like to thank you for your continued support while we work through the negotiations for our skin lightener. The following is...
Sep 13, 2017 04:16 pm ET
Sirona Biochem Announces Resignation of Board Director
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of Dr. Martin Gleave from the board of directors. Dr. Gleave is involved in a new venture that could result in a potential conflict. Accordingly...
Aug 23, 2017 06:06 pm ET
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces an extension to the term of 8,850,770 common share purchase warrants (the "Warrants") originally issued on March 6, 2014. The warrants were issued as part of a private placement....
Jul 06, 2017 08:00 am ET
Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced positive preclinical efficacy data for its library of skin lightening compounds. The study was conducted at Bioalternatives in France, a contract...
Jun 05, 2017 04:18 pm ET
Sirona Biochem Closes Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) is pleased to announce that it has closed the non-brokered private placement (the "Private Placement") of convertible notes ("Notes"). The financing was oversubscribed, resulting...
May 31, 2017 08:00 am ET
Sirona Biochem Announces Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today a non-brokered private placement (the "Private Placement") of convertible notes ("Notes") for gross proceeds of up to $500,000. Each Note will be convertible at...
Apr 20, 2017 04:22 pm ET
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announces an extension to the term of 8,850,770 common share purchase warrants (the "Warrants") originally issued on March 6, 2014. The warrants were issued as part of a private...
Apr 05, 2017 08:00 am ET
Sirona Biochem Announces Keloid Data Accepted for Presentation to the Society of Investigative Dermatology (SID)
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that it has been accepted to present recent data at the 76th Annual Society of Investigative Dermatology (SID) Meeting, April 26-29 in Portland,...
Feb 16, 2017 06:57 pm ET
Sirona Biochem Announces Management Changes
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announces that the Company has terminated Attila Hajdu's employment by mutual agreement. The Company is pleased to announce the addition of Aleksandra Kasikovic to its team in a...
Feb 03, 2017 04:43 pm ET
Sirona Biochem Closes Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) is pleased to announce that it has closed the non-brokered private placement (the "Private Placement") of convertible notes ("Notes"). The financing was oversubscribed, resulting...
Jan 31, 2017 06:33 pm ET
Sirona Biochem Announces Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today a non-brokered private placement (the "Private Placement") of convertible notes ("Notes") for gross proceeds of up to $600,000. Each Note will be convertible at...
Dec 08, 2016 08:00 am ET
Sirona Biochem CEO's Report on Progress
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update. Dear Shareholders,The following is an update on our progress in 2016 and our plans for 2017.Skin Lightener, TFC-1067Throughout 2016, we have...
Oct 25, 2016 05:30 pm ET
Sirona Biochem CEO to Present at French Consulate and Business in France Roundtable Event
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce that CEO, Dr. Howard Verrico, has been invited by the Consulate of France in Vancouver and Business in France to present at a roundtable...
Sep 22, 2016 05:33 pm ET
Sirona Biochem -- Results of Annual General Meeting
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that all resolutions tabled at its Annual General Meeting held on September 21, 2016, were passed. The resolutions included:Fixing the number of...
Jun 30, 2016 08:00 am ET
Sirona Biochem CEO's Report on Progress
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update.Dear Shareholders,I would like to provide an update on our progress.As we enter Q3, our resources continue to be focused on completing a license...
Jun 22, 2016 08:41 pm ET
Sirona Biochem Announces Grant of Stock Options
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that it has granted an aggregate of 400,000 incentive stock options to independent directors of the Company to purchase up to a total of 400,000 common...
Jun 16, 2016 08:00 am ET
Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound SBM-TFC-1067 Accepted as Abstract Presentation by IMCAS
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced positive preclinical safety and efficacy data with SBM-TFC-1067 in a 3-D human skin-like model was accepted as an abstract for oral presentation by...
Jun 13, 2016 08:00 am ET
Sirona Biochem Announces Wanbang Biopharmaceuticals to Proceed to Pre-IND Testing and Receipt of $300,000 USD Milestone Payment
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") today announced that Wanbang Biopharmaceuticals has confirmed they will be proceeding with studies to prepare for Investigational New Drug (IND) filing for the...
May 17, 2016 08:00 am ET
Sirona Biochem to Present New Test Results of SBM-TFC-1067 at Global Conferences
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce participation, in the form of presentations and exhibitions, in several global cosmetic industry conferences."Maintaining a strong presence...
May 11, 2016 09:01 pm ET
Sirona Biochem Announces Close of Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce that it has closed a private placement in the amount of 4,147,500 units at $0.20 per unit for total gross proceeds of $829,500. Each unit...
Apr 18, 2016 08:00 am ET
Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within the skin care portfolio addressing markets with unmet needs. Research...
Apr 11, 2016 08:00 am ET
Sirona Biochem Begins Cell Preservation Research Collaboration With Dr. Caigan Du, University of British Columbia
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that it has entered into a research collaboration with Dr. Caigan Du of the University of British Columbia to study the effects of new compounds,...
Mar 21, 2016 08:00 am ET
Sirona Biochem Selected to Present at BIO-Europe Spring
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe Spring on April 4, 2016, at 10:00 AM CET at the Kistamässan...
Jan 25, 2016 08:00 am ET
Sirona Biochem Invited to Present at Dose of the Valley Conference, San Francisco
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that it has been chosen for a second time, by the Consulate General of Canada, to present at the Dose of the Valley conference on February 9 - 10 in San Francisco,...